![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
#ClinicalTrial EA6192/PET-Stop is a phase II study investigating how well biomarkers on PET/CT imaging can drive early discontinuation of anti-PD-1 therapy in patients with advanced #Melanoma. More info here: https://bit.ly/ea6192pet cc: @MelanomaReAlli, @AIMatMelanoma
Did you know today is #NationalDoctorsDay 🩺? It’s a time to honor the dedication and profound impact of doctors—especially those advancing #cancerresearch. Join us in celebrating their work today!
March is #KidneyCancerAwarenessMonth! Learn about #ClinicalTrial EA8211/SOAR, a study testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. View more info here: https://www.youtube.com/watch?v=v29UtHNXkDs&t=8s cc: @KidneyCancerJ, @kidneycan
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
41
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
